Enhancing photo-fermentation biohydrogen production by strengthening the beneficial metabolic products with catalysts

2021 ◽  
pp. 128437
Author(s):  
Chaoyang Lu ◽  
Wenzhe Li ◽  
Quanguo Zhang ◽  
Linghui Liu ◽  
Ningyuan Zhang ◽  
...  
2020 ◽  
Vol 27 ◽  
Author(s):  
Antonis D. Tsiailanis ◽  
Andreas G. Tzakos ◽  
Thomas Mavromoustakos

: Drugs have to overcome numerous barriers to reach their desired therapeutic targets. In several cases drugs, especially the highly lipophilic molecules, suffer from low solubility and bioavailability and therefore their desired targeting is hampered. In addition, undesired metabolic products might be produced or off-targets could be recognized. Along these lines, nanopharmacology has provided new technological platforms, to overcome these boundaries. Specifically, numerous vehicle platforms such as cyclodextrins and calixarenes have been widely utilized to host lipophilic drugs such as antagonists of the angiotensin II AT1 receptor (AT1R), as well as quercetin and silibinin. The encapsulation of these drugs in supramolecules or other systems refines their solubility and metabolic stability, increases their selectivity and therefore decreases their effective dose and improves the therapeutic index. In this minireview we report on the formulations of Silibinin and AT1R antagonist candesartan in a 2-HP-β-cyclodextrin host molecule, which displayed enhanced cytotoxicity and increased silibinin’s and candesartan’s stability, respectively. Moreover we describe the encapsulation of quercetin in gold nanoparticles bearing a calixarene supramolecular host. Also the encapsulation of temozolomide in a calixarene nanocapsule has been described. Finally, we report on the activity enhancement that has been achieved upon using these formulations as well as the analytical and computational methods we used to characterize these formulations and explore the molecular interactions between the host and quest molecules.


2013 ◽  
Vol 2 (4) ◽  
pp. 345-359 ◽  
Author(s):  
Anniina T. Kivistö ◽  
Alessandro Ciranna ◽  
Ville P. Santala ◽  
Matti T. Karp

2021 ◽  
Vol 46 (31) ◽  
pp. 16565-16590
Author(s):  
Rajesh Banu J ◽  
Mohamed Usman T M ◽  
Kavitha S ◽  
Yukesh Kannah R ◽  
Yogalakshmi K N ◽  
...  

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Biting Wang ◽  
Zengrui Wu ◽  
Weihua Li ◽  
Guixia Liu ◽  
Yun Tang

Abstract Background The traditional Chinese medicine Huangqi decoction (HQD) consists of Radix Astragali and Radix Glycyrrhizae in a ratio of 6: 1, which has been used for the treatment of liver fibrosis. In this study, we tried to elucidate its action of mechanism (MoA) via a combination of metabolomics data, network pharmacology and molecular docking methods. Methods Firstly, we collected prototype components and metabolic products after administration of HQD from a publication. With known and predicted targets, compound-target interactions were obtained. Then, the global compound-liver fibrosis target bipartite network and the HQD-liver fibrosis protein–protein interaction network were constructed, separately. KEGG pathway analysis was applied to further understand the mechanisms related to the target proteins of HQD. Additionally, molecular docking simulation was performed to determine the binding efficiency of compounds with targets. Finally, considering the concentrations of prototype compounds and metabolites of HQD, the critical compound-liver fibrosis target bipartite network was constructed. Results 68 compounds including 17 prototype components and 51 metabolic products were collected. 540 compound-target interactions were obtained between the 68 compounds and 95 targets. Combining network analysis, molecular docking and concentration of compounds, our final results demonstrated that eight compounds (three prototype compounds and five metabolites) and eight targets (CDK1, MMP9, PPARD, PPARG, PTGS2, SERPINE1, TP53, and HIF1A) might contribute to the effects of HQD on liver fibrosis. These interactions would maintain the balance of ECM, reduce liver damage, inhibit hepatocyte apoptosis, and alleviate liver inflammation through five signaling pathways including p53, PPAR, HIF-1, IL-17, and TNF signaling pathway. Conclusions This study provides a new way to understand the MoA of HQD on liver fibrosis by considering the concentrations of components and metabolites, which might be a model for investigation of MoA of other Chinese herbs.


Sign in / Sign up

Export Citation Format

Share Document